Flexible Antibody Formats - Valency Exploration - Intern
Boehringer Ingelheim
Summary
Boehringer Ingelheim is currently seeking a talented and innovative Intern to join our Biotherapeutics Discovery department located at our Ridgefield, CT facility. As an Intern, you will contribute to the development of an innovative antibody engineering platform designed to accelerate multispecific antibody format evaluation. This project focuses on creating a flexible workflow that enables rapid conversion between IgG1KO and ZM21 antibody formats through hinge engineering and protease-mediated cleavage strategies.
Job description
The successful candidate will gain hands-on experience in antibody engineering, molecular biology, protein expression, purification, and biophysical characterization while working alongside a multidisciplinary team of scientists developing next-generation biotherapeutics.
Duties & Responsibilities
- Design and generate antibody variants using molecular biology techniques
- Express recombinant antibodies using transient mammalian expression systems
- Purify antibody molecules using standard protein purification methods
- Characterize protein expression, yield, purity, and product quality attributes
- Document findings and communicate results through presentations and written summaries
- Collaborate with scientists across Biotherapeutics Discovery
Requirements
- Must be a current graduate or advanced degree student in good academic standing
- Student must be enrolled at an accredited college or university for the duration of the internship
- Overall cumulative minimum GPA from last completed quarter/semester 3.0 GPA (on a 4.0 scale) preferred
- Major or minor in Biology, Biochemistry, Biotechnology, Chemical Engineering, Biomedical Engineering or related field of internship
- Undergraduate students must have completed at least 12 credit hours at current college or university
- Graduate and advanced degree students must have completed at least 9 credit hours at current college or university
- Basic understanding of molecular biology, protein biochemistry, or antibody engineering
- Strong analytical, organizational, and communication skills
- Ability to work independently and collaboratively in a team environment
Desired Qualifications
- Prior laboratory experience with molecular cloning, mutagenesis, mammalian cell culture, or protein purification
- Familiarity with antibody structure and function
- Experience analyzing biochemical or biophysical data
Eligibility Requirements
- Must be legally authorized to work in the United States without restriction
- Must be willing to take a drug test and post-offer physical (if required)
- Must be 18 years of age or older
Requirements
- Must be a current graduate or advanced degree student in good academic standing
- Student must be enrolled at an accredited college or university for the duration of the internship
- Major or minor in Biology, Biochemistry, Biotechnology, Chemical Engineering, Biomedical Engineering or related field
- Undergraduate students must have completed at least 12 credit hours at current college or university
- Graduate and advanced degree students must have completed at least 9 credit hours at current college or university
- Basic understanding of molecular biology, protein biochemistry, or antibody engineering
- Strong analytical, organizational, and communication skills
- Ability to work independently and collaboratively in a team environment
- Must be legally authorized to work in the United States without restriction
- Must be willing to take a drug test and post-offer physical (if required)
- Must be 18 years of age or older
Benefits
- Medical Coverage
- Paid Time Off
- Paid Holidays
- Disability Insurance
- Life Insurance
- Company-Sponsored Benefits
Company overview
Boehringer Ingelheim is a leading global research-driven biopharmaceutical company founded in 1885 and headquartered in Ingelheim am Rhein, Germany. As one of the world's top 20 pharmaceutical companies and the largest privately-owned pharmaceutical firm, it operates across three main business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. The company focuses on developing innovative therapies for diseases with high unmet medical needs, including cardiometabolic diseases, oncology, respiratory diseases, immunology, central nervous system disorders, and retinal health. With over 54,500 employees across 78 countries, Boehringer Ingelheim generated approximately €26.8 billion in revenue in 2024. The company maintains a strong research and development network with facilities in Germany, the United States, Austria, Japan, and Switzerland, investing significantly in advancing treatments for both human and animal health. Notable products include Jardiance (empagliflozin) for diabetes, Ofev (nintedanib) for pulmonary fibrosis, Spiriva (tiotropium) for respiratory conditions, and Pradaxa (dabigatran) for anticoagulation therapy.